An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer

@inproceedings{Kozloff2010AnES,
  title={An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer},
  author={Mark F. Kozloff and Ellen Chuang and Alexander Starr and Penelope A. Gowland and Patricia E Cataruozolo and Mary A. Collier and Lev Verkh and Xin Huang and Kenneth A. Kern and Kathy D. Miller},
  booktitle={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2010}
}
BACKGROUND Sunitinib has shown single-agent activity in patients with previously treated metastatic breast cancer (MBC). We investigated the safety of the combination of sunitinib and paclitaxel in an exploratory study of patients with locally advanced or MBC. METHODS Patients received oral sunitinib 25 mg/day (with escalation to 37.5 mg/day as tolerated… CONTINUE READING